Biography

YAN Juming, Professor, Doctoral Supervisor, and Postdoctoral Mentor, is a tumor immunologist. As a principal investigator, Juming is leading the Immunology and Metabolism Research Group at the Jiangsu Key Laboratory of Immunity and Metabolism, Xuzhou Medical University. He received Ph.D. training at the University of Queensland Australia. After he obtained his Ph.D. in basic biomedicine research, he moved to QIMR Berghofer in 2018 to work on cancer immunology as a Postdoc. His research is primarily dedicated to exploring the mechanisms of tumor immune evasion, identifying new targets, and developing new strategies and immunotherapeutic drugs including small molecule compounds and antibodies, and Immune cell transfer therapy for tumors. His research has been published in high-level immunology and oncology journals such as Cancer Discovery, PNAS, Nature Immunology, and Cancer Immunology Research, with a citation 1,700 times, an H-index of 18. He has applied for six invention patents as the first inventor, with two patents granted. His research was founded by the National and Jiangsu Province Science Foundation of China. His research group currently consists of three lecturers, two full-time postdoctoral researchers, one doctoral student, and eight master's students.

Publications

Representative publications:

1. Dongchen Yuan^#, Jing Hu^#*, Xiaoman Ju^#, Eva Maria Putz, Simin Zheng, Stephane Koda, Guowei Sun, Xiaoran Deng, Zhipeng Xu, Wei Nie, Yang Zhao, Xianyang Li, William C. Dougall, Simin Shao, Yan Chen, Renxian Tang, Kuiyang Zheng*, Juming Yan*. NMDAR antagonists suppress tumor progression by regulating tumor-associated macrophages. PNAS. 2023. 120(47): 124-141. impact factor 121.1.

2.Juming Yan, Stacey Allen, Indrajit Das, Elizabeth McDonald, Jeffrey Y.W. Mak, Ligong Liu, David P. Fairlie, Bronwyn S. Meehan, Zhenjun Chen, Alexandra J. Corbett, Antiopi Varelias, Mark J. Smyth, Michele W.L. Teng. MAIT Cells Promote Tumor Initiation, Growth and Metastases via Tumor MR1. Cancer Discovery. 2020. 10(1): 124-141 Impact factor 39.397.

3.Juming Yan^#, Xian-Yang Li^#, Amelia Roman Aguilera, Christos Xiao, Simon C. Robson, Courtney Beers, Achim K. Moesta, Nishamol Geetha, Michele W. L. Teng et al. Control of metastases via myeloid CD39 and NK cell effector function. Cancer Immunology Research. 2020. 8(3), 356-367. Impact factor: 11.151.

4.Juming Yan, Stacey Allen, Dipti Vijayan, Xianyang Li, Heidi Harjunpää, Kazuyoshi Takeda, Jing Liu, Daniel J. Cua, Mark J Smyth, and Michele WL Teng. Experimental lung metastases in mice are more effectively inhibited by blockade of IL23R than IL23. Cancer Immunology Research 2018. 6(8):978-987. Impact factor 8.619.

5.Juming Yan, Mark J Smyth, and Michele WL Teng. Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer. Cold Spring Harbor perspectives in Biology. 2018. 10(7):a028530. Impact factor 10.25.

6.Stephane Koda^#, Jing Hu^#, Xiaoman Ju, Guowei Sun, Simin Shao, Ren-xian Tang, Kui-yang Zheng*, Juming Yan*. The role of glutamate receptors in the regulation of the tumor microenvironment. Frontiers in Immunology. 2023. 1(14)1123841. Impact factor 7.3.

7.Juming Yan, Daniel J Cua, and Michele WLTeng. IL-23 promotes the development of castration-resistant prostate cancer. Immunology and cell biology. 2018. 96(9):883-885. Impact factor 3.947.

8.Susanna S. Ng, Fabian De Labastida Rivera, Juming Yan, Dillon Corvino, Indrajit Das, Ping Zhang, Rachel Kuns, Shashi Bhushan Chauhan, Jiajie Hou, Xian-Yang Li, Teija C M Frame, Benjamin A McEnroe, Eilish Moore, Jinrui Na, Jessica A Engel, Megan S F Soon, Bhawana Singh, Andrew J Kueh, Marco J Herold, Marcela Montes de Oca, Siddharth Sankar Singh, Patrick T Bunn, Amy Roman Aguilera, Mika Casey, Matthias Braun, Nazanin Ghazanfari, Shivangi Wani, Yulin Wang, Fiona H Amante, Chelsea L Edwards, Ashraful Haque, William C Dougall, Om Prakash Singh, Alan G Baxter, Michele W L Teng, Alex Loukas, Norelle L Daly, Nicole Cloonan, Mariapia A Degli-Esposti, Jude Uzonna, William R Heath, Tobias Bald, Siok-Keen Tey, Kyohei Nakamura, Geoffrey R Hill, Rajiv Kumar, Shyam Sundar, Mark J Smyth, Christian R Engwerda. The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. Nature Immunology. 2020. 21(10): 1205-1218. Impact factor: 25.606.

9.Maya Kansara, Kristian Thomson, Puiyi Pang, Aurelie Dutour, Lisa Mirabello, Francine Acher, Jean-Philippe Pin, Juming Yan, Michele W.L. Teng, Mark J. Smyth, David M. Thomas. Infiltrating myeloid cells drive osteosarcoma progression via GRM4 regulation of IL23. Cancer Discovery. 2019. 9(11):1511-1519. Impact factor 29.479.

10.Yulong Gao, Fernando Souza-Fonseca-Guimaraes, Tobias Bald, Susanna S Ng, Arabella Young, Shin Foong Ngiow, Jai Rautela, Jasmin Straube, Nic Waddell, Stephen J Blake, Juming Yan, Laurent Bartholin, Jason S Lee, Eric Vivier, Kazuyoshi Takeda, Meriem Messaoudene, Laurence Zitvogel, Michele WL Teng, Gabrielle T Belz, Christian R Engwerda, Nicholas D Huntington, Kyohei Nakamura, Michael Holzel, and Mark J Smyth. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nature Immunology. 2017.18(9):1004-1015. Impact factor 21.506.

11.Hongyu Zhou, Chunlei Yu, Lingmei Kong, Xiaoliang Xu, Juming Yan, Yingchao Li, Tao An, Liang Gong, Yaxiao Gong, and Huifang Zhu, Hongbin Zhang, Xiaodong Yang, Yan Li. B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells. Oncogene. 2019. 38(18):3371. Impactor factor 7.971.

12.Jing Liu, Jake S O’donnell, Juming Yan, Jason Madore, Stacey Allen, Mark J Smyth, and Michele WL Teng. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. OncoImmunology. 2019. 8(5):e1581530. Impact factor 5.333.

13.Heidi Harjunpää, Stephen J Blake, Elizabeth Ahern, Stacey Allen, Jing Liu, Juming Yan, Viviana Lutzky, Kazuyoshi Takeda, Amy Roman Aguilera, Camille Guillerey, Deepak Mittal, Xian Yang Li, William C Dougall, Mark J Smyth, Michele WL Teng. Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. Oncoimmunology. 2018. 7(7):e1445949. Impact factor 7.72.

14.Cheng Qian, Yueke Zhou, Teng Zhang, Guanglu Dong, Mengyao Song, Yu Tang, Zhonghong Wei, Suyun Yu, Qiuhong Shen, Wenxing Chen, Jaesung P Choi, Juming Yan, Chongjin Zhong, Li Wan, Jia Li, Aiyun Wang, Yin Lu, Yang Zhao. Targeting PKM2 signaling cascade with salvianic acid A normalizes tumor blood vessels to facilitate chemotherapeutic drug delivery. Acta Pharmaceutica Sinica B. 2024. 14(5): 2077-2096. Impact factor 14.7.

15.Jin-Mei Liu, Min Wang, Yun-Jingzhou, Juming Yan, Li-Juan Yang, Yan Li, Hong-Bin Zhanga, and Xiao-Dong Yang. Novel 3-substituted fluorine imidazolium/triazolium salt derivatives: synthesis and antitumor activity. RSC Advance. 2015. 5(78):63936–63944. Impact factor 3.289.

16.Xinyao Li, Bing Bai, L Liu, P Ma, Lingmei Kong, Juming Yan, Jing Zhang, Zhennan Ye, Hongyu Zhou, Bingyu Mao, Huajie Zhu, and Yan Li. Novel beta-carbolines against colorectal cancer cell growth via inhibition of Wnt/beta-catenin signaling. Cell Death Discovery. 2015. 1:15033.

17.Hongyu Zhou, Tao Shen, Chaowei Shang, Yan Luo, Lei Liu, Juming Yan, Yan Li, and Shile Huang. Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway. Oncotarget. 2014. 5(20):10140-50. Impact factor 6.359.

18.Fang Wang, Juming Yan, Yanfen Niu, Yan Li, Hua Lin, Xu Liu, Jikai Liu, and Ling Li. Mangiferin and its aglycone, norathyriol, improve glucose metabolism by activation of AMP-activated protein kinase. Pharmaceutical Biology. 2014. 52(1):68-73. Impact factor 1.241.

19.Chengqin Liang, Ronghua Luo, Juming Yan, Yan Li, Xiaonian Li, Yiming Shi, Shanzhai Shang, Zhonghua Gao, Liumeng Yang, Yongtang Zheng, Weilie Xiao, Hongbbin Zhang, and Handong Sun. Structure and bioactivity of triterpenoids from the stems of Schisandra sphenanthera. Archives of Pharmacal Research. 2014. 37(2):168-74. Impact factor 1.751.

20.Juming Yan, Hongyu Zhou, Lingmei Kong, Jing Zhang, Qinshi Zhao, and Yan Li. Identification of two novel inhibitors of mTOR signaling pathway based on high content screening. Cancer Chemotherapy and Pharmacology. 2013. 72(4):799-808. Impact factor 2.571.

21.Jia Su, Peiji Zhao, Lingmei Kong, Xingyao Li, Juming Yan, Ying Zeng, and Yan Li. Trichothecin induces cell death in NF-kappaB constitutively activated human cancer cells via inhibition of IKKbeta phosphorylation. PLoS One. 2013. 8(8):e71333. Impact factor 4.05.